GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
GeoVax Labs, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| NIH Grants [Member] | $81.53K | $385.50K | $1.44M | $983.68K | $934.58K | $980.27K | $828.92K | 100.0% | -78.9% |
| Government Contract [Member] | – | – | – | – | $28.63K | $95.00K | $0 | – | – |
| Research Agreements [Member] | – | – | $385.19K | $192.21K | $28.63K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of GeoVax Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.